- OP Labs formerly Oxford Peptides
- Batch HPLC tested at ≥ 99% purity
- Storage: –20 °C long term; 2–8 °C short term
- Sold for research purposes only
FOXO4 Peptide (FOXO4-DRI)
Synonyms: FOXO4-DRI, FOXO4 inhibitory peptide, FOXO4 decoy peptide
CAS Number: N/A
Peptide Classification: Synthetic modified peptide; protein–protein interaction inhibitor
Molecular Formula: C228H388N86O64
Molecular Weight: 5358.05 g/mol
Appearance: White to off-white lyophilised powder
Purity: ≥ 99% (HPLC, typical)
Solubility: Soluble in water and buffered aqueous solutions
Storage: –20 °C, desiccated, protected from light
Pack Size: 10mg
Description & Mechanism
FOXO4-DRI is a synthetic, modified peptide derived from regions of the Forkhead box O4 (FOXO4) transcription factor. It was engineered using a D-retro-inverso design to improve stability and resistance to proteolytic degradation in experimental systems.
In biochemical and cellular research models, FOXO4-DRI has been used to study protein–protein interactions between FOXO4 and p53. The peptide acts as a competitive inhibitor of this interaction, enabling investigation of transcriptional regulation, apoptosis and stress-response signalling. Observed effects are dependent on experimental design, concentration, and model system, and are used for mechanistic exploration rather than defined biological outcomes.
Applications in Research
• Investigation of FOXO4–p53 protein–protein interactions
• Study of apoptosis signalling and transcription factor regulation
• In vitro models examining stress-response signalling pathways
• Use as a research tool in cell-cycle biology studies
Specifications Summary
Purity: ≥ 99% (HPLC)
Appearance: White to off-white lyophilised powder
Peptide Type: Synthetic modified research peptide
Molecular Weight: 5358.05 g/mol
Solubility: Water, buffered aqueous solutions
Storage: –20 °C, desiccated, protected from light
Precautions & Notes
• Intended strictly for laboratory research use
• Not for human or veterinary application
• Experimental outcomes may vary depending on model system and assay design
• Appropriate controls are recommended to interpret pathway-specific effects
References
Calnan D.R., Brunet A. The FoxO code. Oncogene, 2008.
https://pubmed.ncbi.nlm.nih.gov/18391970/
Keywords: FOXO4, FOXO4-DRI, FOXO4 peptide, p53 interaction inhibitor








